Загрузка...
Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm
With 6 agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (ie axitinib and tivozanib) abide by the same paradigm as existing drugs...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3297694/ https://ncbi.nlm.nih.gov/pubmed/22351744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-11-0806 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|